P2d, Inc.

Cincinnati, OH 45242

SBIR Award Summary

Total Number of Awards 46
Total Value of Awards $17.7MM
First Award Date 06/01/05
Most Recent Award Date 09/15/17

Key Personnel

Last Name Name Awards Contact
Bezerra Jorge A. Bezerra 4
Zemlan Frank Zemlan 17
Gabbita Somasundar Prasad Gabbita 12
Mulchahey James Jeffrey Mulchahey 1
Norman Andrew B Norman 4
Filippi Marie-Dominique Filippi 1
Webb Cheryle Branch Webb 1
Benoit Stephen C Benoit 3
Geiger Hartmut Geiger 5
Zheng Yi Zheng 4
Harris-White Marni E Harris-White 5
Cancelas Jose A Cancelas 2
Pierce Charles Harmon Pierce 1
MULLOY JAMES C MULLOY 1
ABU-EL-HAIJA MAISAM ABU-EL-HAIJA 1

46 Awards Won

Phase SBIR

Agency: Department of Health & Human Services
Topic: PAR-16-027
Budget: 09/15/17 - 05/31/18

ABSTRACT The goal of this proposal is to develop tumor necrosis factor ? (TNF?)-inhibiting compounds as neuroprotectant drugs for treating Alzheimer?s disease (AD). Current FDA-approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease progression. Thus, a critical n...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-065
Budget: 04/14/17 - 03/31/18
PI: Yi Zheng

ABSTRACT The purpose of the proposed grant application is to further develop a therapeutic regimen focused on radiological/nuclear medical countermeasures. Very few medical products have been shown to counter the acute and long-term injuries that can result from a nuclear or radiological accident or attack. Medical products and regimens that mit...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 06/01/16 - 05/31/17

? DESCRIPTION (provided by applicant): The goal of this proposal is to develop tumor necrosis factor a (TNFa)-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Current FDA-approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/01/15 - 05/31/16

DESCRIPTION (provided by applicant): The goal of this proposal is to develop tumor necrosis factor a (TNFa)-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Current FDA-approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease pro...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 03/01/15 - 02/28/16

DESCRIPTION (provided by applicant): Genetic mutations are known to cause acute and chronic liver diseases, and are being increasingly recognized as drivers of phenotype severity. As a group, these diseases represent a substantial disease burden in the United States, and constitute a diagnostic challenge in the clinical evaluation of affected pa...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 03/01/15 - 02/29/16

DESCRIPTION (provided by applicant): Pancreatitis is a painful condition that may become recurrent or chronic in genetically susceptible individuals. Patients with pancreatitis suffer multiple hospital admissions, pain episodes, addiction to pain medications, and psychosocial stressors by missing school by the child and work by family members. A...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 08/01/14 - 01/31/15

DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 08/01/14 - 07/31/15

ABSTRACT The use of platelet transfusions has increased dramatically since 1980s, but a safe, long-term platelet storage method remains missing. Current practice has platelets stored at 20 to 24C after preparation, which has a limited lifetime up to 5 days primarily due to concerns about bacterial contamination. Refrigerated storage reduces plat...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 06/15/14 - 05/31/15

DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (AD). The core symptom of AD is short-term memory impairment. (DSM-IV) In preliminary studies, PD2XXX improved short term memory by over 110% in a well-ac...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 04/01/14 - 02/28/15

DESCRIPTION (provided by applicant): Genetic mutations are known to cause acute and chronic liver diseases, and are being increasingly recognized as drivers of phenotype severity. As a group, these diseases represent a substantial disease burden in the United States, and constitute a diagnostic challenge in the clinical evaluation of affected pa...

Load More